Regulating effect of Xuefuzhuyu capsule on clopidogrel resistance in patients with severe blood stasis syndrome after PCI operation
-
摘要: 目的 观察血府逐瘀胶囊联合氯吡格雷治疗氯吡格雷抵抗患者的效果，评价其改善氯吡格雷抵抗作用的效果。 方法 经皮冠状动脉介入治疗（PCI）术后氯吡格雷抵抗患者80人，随机分组，分别给予3种药物治疗方案：A组用国产氯吡格雷（泰嘉）加用血府逐瘀胶囊；B组使用进口氯吡格雷（波立维）；C组用国产氯吡格雷（泰嘉）加用西洛他唑，连续3个月，采用血栓弹力图法检测干预后血小板抑制率。并随访患者半年，观察临床不良事件的发生率。 结果 治疗3个月后，各组抑制率均有所提高，且均有显著差异（P<0.05）。A组对血小板抑制的有效率达40%，优于C组（33.33%），与B组相当（40.74%）。对阿司匹林、氯吡格雷均不敏感的患者换用进口波立维对提高血小板抑制效果更佳；仅对氯吡格雷不敏感的患者加用血府逐瘀胶囊对血小板抑制有协同作用。随访半年后发现，联合使用血府逐瘀胶囊的时间延长可能会增强血小板抑制的效果，但并不增加出血及凝血功能异常等风险。 结论 血府逐瘀胶囊对提高血小板抑制率有一定的作用，同时对出血风险影响较小。Abstract: Objective To observe and evaluate the regulating effect of Xuefuzhuyu capsule combined with clopidogrel on clopidogrel resistance. Methods After PCI operation, 80 patients with clopidogrel resistance were randomly divided into three different treatments,A:clopidogrel (Tai Jia) combined with Xuefuzhuyu capsule; B:clopidogrel (Plavix); C:clopidogrel (Tai Jia) combined with cilostazol.)After three months of continuous medication, and the inhibition rate of platelet aggregation was detected by thromboela-stogram(TEG).The patients were followed up for half a year to observe the incidence of adverse events. Results After three months of treatment, the inhibition rates of the three groups were improved(P<0.05).The effective rate of platelet inhibition in group A was 40% (10/25), which was higher to group C (33.33%), and which was equivalent to group B (40.74%). The effect of platelet aggregation inhibition was better in patients who were not sensitive to aspirin and clopidogrel and then with imported Plavix. And the treatment group of clopidogrel combined with Xuefuzhuyu capsule had a synergistic effect on platelet aggregation inhibition for clopidogrel insensitive patients. After six months' follow-up, it was found that the platelet inhibition was enhanced but the bleeding risk and abnormal coagulation function was not increased after prolonged using of Xuefuzhuyu capsule. Conclusion Xuefuzhuyu capsule had a certain effect on improving the inhibition rate of platelet aggregation, which had little effect on the risk of bleeding.
-
[1] VLACHOJANNIS GJ, DIMITROPOULOS G, ALEXOPOULOS D.Clopidogrel resistance:current aspects and future directions[J]. Hellenic J Cardiol,2011,52(3):236-245. [2] 余长永,张勇,邹建军,等.氯吡格雷抵抗原因及对策的研究进展[J].中国临床药理学与治疗学,2009,14(10):1168-1173. [3] 陈慧,严威,吴小盈,等. 血瘀证CYP2C19基因多态性与氯吡格雷抵抗和PCI术预后的关系[J]. 中国中西医结合杂志,2010,30(12):1245-1249. [4] 张文将,邓冰湘. 血府逐瘀汤抗动脉血栓形成及其作用机制的研究进展[J]. 湖南中医药大学学报,2013,33(4):102-104. [5] 王阶,陈可冀,翁维良,等. 血瘀证诊断标准的研究[J]. 中西医结合杂志,1988,8(10):585-589. [6] 陈可冀, 史载祥. 实用血瘀证学[M]. 北京:人民卫生出版社,1999:17-23. [7] 陈伯钧,潘宗奇,苏学旭,等.冠心病介入治疗前后中医证型变化的研究[J].中国中西医结合杂志,2007,27(8):689-691. [8] 褚福永,王阶,孙晓伟,等. 血府逐瘀胶囊改善不稳定型心绞痛介入术后血瘀证患者近期生活质量的随机双盲对照试验[J]. 中西医结合学报,2009,7(8):729-735. [9] 涂金生,黄春兰.氯吡格雷对非ST段抬高冠脉综合征患者炎性因子及预后的影响[J].临床合理用药杂志,2015,8(3):84-85. -
点击查看大图
计量
- 文章访问数: 2898
- HTML全文浏览量: 313
- PDF下载量: 379
- 被引次数: 0
下载:
